SCHEMBL35210767

SCHEMBL35210767

O=C(c1cccc(F)c1)c1ccc2scc(C3=CCN4CCCCC4CC3)c2c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.41
HTT P42858 1/20 0.41
HRH3 Q9Y5N1 3/20 0.40
HTR1D P28221 1/20 0.37
HTR1B P28222 1/20 0.37
KMT2A Q03164 1/20 0.34
TP53 P04637 2/20 0.34
MAPT P10636 2/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
USP2 O75604 1/20 0.34
LMNA P02545 1/20 0.34
L3MBTL3 Q96JM7 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRK1 P41145 1/20 0.33
KDM2B Q8NHM5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8724062 0.90 HRH3 (0.40) HRH3HTR1DHTR1BKMT2AL3MBTL3
SCHEMBL8720766 0.89 HRH3 (0.38) HRH3TP53MAPTUSP2LMNA
SCHEMBL8720752 0.83 MEN1 (0.38) TDP1HTTHRH3KMT2AMAPT
SCHEMBL30908873 0.83 HRH3 (0.39) HRH3HTR1DHTR1BL3MBTL3L3MBTL1
SCHEMBL30909167 0.82 HRH3 (0.38) HTTHRH3KMT2ATP53MAPT
SCHEMBL8724021 0.81 HTR1F (0.40) HTTHRH3HTR1DHTR1BTP53
SCHEMBL8721871 0.80 HRH3 (0.40) HRH3HTR1DHTR1BKMT2ATP53
SCHEMBL8724259 0.79 HRH3 (0.39) TDP1HRH3KMT2AKDM4EALDH1A1
SCHEMBL8720711 0.79 TP53 (0.44) TDP1HTTKMT2ATP53MAPT
SCHEMBL8725926 0.78 TDP1 (0.41) TDP1HTTKMT2ATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D TDP1 1651/4885HTT 131/4885HRH3 126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.